脊髓性肌萎缩的单剂量基因替代治疗
该研究纳入15例脊髓性肌萎缩1型(SMA1)患儿,单次静脉输注携带SMN1 cDNA的腺相关病毒血清型9(AAV9),3例接受低剂量(6.7×10^13 vg/kg),12例接受高剂量(2.0×10^14 vg/kg)。主要终点为安全性,次要终点为至死亡或需永久通气辅助的时间。截至2017年8月7日数据截止,全部15例存活且无事件至20月龄,历史队列存活率为8%。高剂量组CHOP INTEND评分较基线快速升高,1个月增加9.8分,3个月增加15.4分,而历史队列该评分下降;12例高剂量患儿中11例可独坐、9例可翻身、11例可经口进食并说话、2例可独立行走。4例出现血清转氨酶升高,经泼尼松治疗后减轻。
要点
- 15例SMA1患儿单次静脉输注AAV9-SMN1,低剂量6.7×10^13 vg/kg(3例)或高剂量2.0×10^14 vg/kg(12例)。
- 截至2017年8月7日,全部15例存活且无事件至20月龄,历史队列存活率为8%。
- 高剂量组CHOP INTEND评分1个月较基线增加9.8分、3个月增加15.4分,历史队列同期下降。
- 12例高剂量患儿中11例独坐、9例翻身、11例经口进食并说话、2例独立行走。
- 4例出现血清转氨酶升高,经泼尼松治疗后减轻;结论认为需进一步研究确认安全性和有效性。
适用人群与场景
- 15例脊髓性肌萎缩1型(SMA1)患儿,婴儿期起病,未能达到运动里程碑。
处置流程与药物剂量
- 单次静脉输注携带SMN1 cDNA的腺相关病毒血清型9(AAV9):低剂量6.7×10^13 vg/kg(3例),高剂量2.0×10^14 vg/kg(12例)。
- 4例出现血清转氨酶升高,经泼尼松治疗后减轻。
研究设计与关键结果
- 研究类型为单臂研究,15例SMA1患儿接受单次静脉AAV9-SMN1输注,主要终点为安全性,次要终点为至死亡或需永久通气辅助的时间。
- 截至2017年8月7日数据截止,全部15例存活且无事件至20月龄,历史队列存活率为8%。
- 高剂量组CHOP INTEND评分(0–64分,分值越高功能越好)较基线快速升高:1个月增加9.8分,3个月增加15.4分;历史队列该评分下降。
- 12例高剂量患儿中,11例可独坐、9例可翻身、11例可经口进食并说话、2例可独立行走。
- 4例出现血清转氨酶升高,经泼尼松治疗后减轻。
证据类型、等级与局限
- 证据类型:单臂研究(15例),以历史队列为对照进行探索性分析。
- 局限:原文结论指出需进一步研究确认该基因治疗的安全性和有效性。
对床旁实践的改变
- 作者认为,在SMA1患者中,单次静脉输注含SMN编码DNA的腺相关病毒载体较历史队列可获得更长生存、更优运动里程碑达成和更好运动功能。
- 作者指出,需进一步研究确认该基因治疗的安全性和有效性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease.
METHODS: Fifteen patients with SMA1 received a single dose of intravenous adeno-associated virus serotype 9 carrying SMN complementary DNA encoding the missing SMN protein. Three of the patients received a low dose (6.7×1013 vg per kilogram of body weight), and 12 received a high dose (2.0×1014 vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts).
RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone.
CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
参考来源
- Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017. PMID: 29091557. doi:10.1056/NEJMoa1706198
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。